April 5, 2018 A group of pharmaceutical companies is facing a lawsuit alleging the defendants entered into an unlawful antitrust agreement that allowed them to reap significant profits from the sales of Zetia and its generic by delaying market competition.
March 5, 2018 A proposed class action has been filed against a group of pharmaceutical companies claiming they conspired to delay the entrance of generic alternatives to Zetia into the market, thereby overcharging consumers by “tens of millions of dollars.”
February 6, 2018 Merck & Co., Inc., Glenmark Pharmaceuticals, Ltd., and several of their respective subsidiaries are facing a lawsuit that claims the parties unlawfully delayed the launch of generic alternatives to Merck’s brand name high cholesterol drug, Zetia.
